Johnson & Johnson - 15 Year Stock Price History | JNJ
Historical daily share price chart and data for Johnson & Johnson since 2011 adjusted for splits and dividends. The latest closing stock price for Johnson & Johnson as of September 04, 2026 is 275.23.
- The all-time high Johnson & Johnson stock closing price was 278.43 on September 03, 2026.
- The Johnson & Johnson 52-week high stock price is 281.07, which is 2.1% above the current share price.
- The Johnson & Johnson 52-week low stock price is 173.33, which is 37% below the current share price.
- The average Johnson & Johnson stock price for the last 52 weeks is 225.72.
| Johnson & Johnson Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 238.9229 | 204.0460 | 278.4300 | 201.0550 | 275.2300 | 35.15% |
| 2025 | 165.1529 | 137.5180 | 210.7580 | 135.6470 | 203.6530 | 47.48% |
| 2024 | 146.1270 | 148.0610 | 158.5520 | 134.7110 | 138.0910 | -4.81% |
| 2023 | 146.0490 | 160.0670 | 161.9180 | 133.6900 | 145.0710 | -8.58% |
| 2022 | 152.9387 | 150.1490 | 163.8590 | 139.3080 | 158.6840 | 5.98% |
| 2021 | 143.0014 | 133.6170 | 155.1450 | 131.5030 | 149.7370 | 11.44% |
| 2020 | 122.7798 | 121.3280 | 134.3680 | 92.9669 | 134.3680 | 10.82% |
| 2019 | 110.5294 | 103.2730 | 121.7190 | 101.6320 | 121.2450 | 16.22% |
| 2018 | 106.0618 | 109.5810 | 119.5130 | 95.2768 | 104.3240 | -5.13% |
| 2017 | 100.8381 | 88.8629 | 112.4610 | 85.7330 | 109.9660 | 24.42% |
| 2016 | 85.9779 | 74.9613 | 94.9032 | 71.4326 | 88.3796 | 15.33% |
| 2015 | 73.3091 | 75.7308 | 78.5199 | 67.1922 | 76.6324 | 1.14% |
| 2014 | 72.0793 | 64.1772 | 78.6291 | 61.0681 | 75.7670 | 17.34% |
| 2013 | 59.5946 | 48.4709 | 67.4202 | 48.4025 | 64.5720 | 34.62% |
| 2012 | 44.9673 | 43.4687 | 49.1854 | 41.5239 | 47.9646 | 10.85% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $663.276B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1081.958B | 36.50 |
| AbbVie (ABBV) | United States | $453.112B | 23.59 |
| Merck (MRK) | United States | $370.890B | 46.83 |
| Roche Holding AG (RHHBY) | Switzerland | $350.157B | 0.00 |
| Novartis AG (NVS) | Switzerland | $305.285B | 18.43 |
| Novo Nordisk (NVO) | Denmark | $208.069B | 11.59 |
| Pfizer (PFE) | United States | $162.156B | 9.33 |
| Sanofi (SNY) | France | $107.257B | 9.03 |
| Bayer (BAYRY) | Germany | $55.767B | 9.92 |
| Innoviva (INVA) | United States | $1.541B | 5.27 |